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Abstract
 
We generated purine nucleoside phosphorylase (PNP)-deficient mice to gain insight into the
mechanism of immune deficiency disease associated with PNP deficiency in humans. Similar to
the human disease, PNP deficiency in mice causes an immunodeficiency that affects T lym-
phocytes more severely than B lymphocytes. PNP knockout mice exhibit impaired thymocyte
differentiation, reduced mitogenic and allogeneic responses, and decreased numbers of matur-
ing thymocytes and peripheral T cells. T lymphocytes of PNP-deficient mice exhibit increased
apoptosis in vivo and higher sensitivity to gamma irradiation in vitro. We propose that the im-
mune deficiency in PNP deficiency is a result of inhibition of mitochondrial DNA repair due
to the accumulation of dGTP in the mitochondria. The end result is increased sensitivity of T
cells to spontaneous mitochondrial DNA damage, leading to T cell depletion by apoptosis.
Key words: immune deﬁciency • apoptosis • mitochondria • purine metabolism • 
T lymphocyte
 
Introduction
 
An inherited deficiency in either one of the two purine sal-
vage enzymes adenosine deaminase (ADA)
 
1
 
 or purine nu-
cleoside phosphorylase (PNP) causes SCID disease (1, 2).
Studies with mouse lymphoma T cell lines suggested that
the impaired degradation of deoxyribonucleoside substrates
of ADA and PNP leads respectively to accumulation of
dATP or dGTP, which can inhibit ribonucleotide reductase
activity, abrogating DNA synthesis or DNA repair (Fig. 1;
references 3–6). dATP, but not dGTP, has also been found
to form a complex with apoptotic protease-activating factor
1 (Apaf-1) and cytochrome C in the cytoplasm to activate
caspases and induce apoptosis (7). Other mechanisms may
also contribute to immunodeficiency associated with ADA
deficiency, the more actively studied of the two disorders
(8). However, the basis for immunodeficiency in PNP defi-
ciency is still uncertain. Mice with PNP deficiency due to
missense mutations showed a decline with age in numbers
of immature and peripheral T cells and in T cell prolifera-
tion (9). These mice exhibited delayed immune deficiency
characterized by a reduction in the numbers of immature
and peripheral T cells and reduced T cell proliferation. In
addition, mutations in PNP caused a secondary loss of
deoxyguanosine kinase activity. The mechanism of the par-
tial immune deficiency in these mice was not addressed.
To better address the mechanism of immunodeficiency,
we generated totally PNP-deficient mice by homologous
recombination. At an early age, PNP knockout mice ex-
hibit T cell lymphopenia and abnormalities in T cell func-
tion. We propose that the abnormalities are due to selective
accumulation of dGTP in the mitochondria of T cells,
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Abbreviations used in this paper:
 
 ADA, adenosine deaminase; 
 
Dc
 
m
 
, mito-
chondrial membrane potential; DN, double negative; DP, double positive;
MNGIE, neurogastrointestinal encephalomyopathy; PNP, purine nucleo-
side phosphorylase; SP, single positive; TP, thymidine phosphorylase. 
2198
 
Purine Nucleoside Phosphorylase–deficient Immune-deficient Mice
 
leading to defective mitochondrial DNA repair and T cell
apoptosis.
 
Materials and Methods
 
Generation of PNP
 
2
 
/
 
2
 
 Mutant Mice.
 
Murine cDNA for PNP
was used for screening genomic library of 129/Cj in 
 
l
 
DASH
phage vectors. Genomic clones were mapped and partially se-
quenced. A 7.0-kb genomic fragment containing the PNP cata-
lytic sites within exons 3 and 4 was used to construct the
targeting vector. A 1.2-kb genomic HindIII fragment containing
exons 3 and 4 was replaced with a PGK
 
neo
 
-polA G418 resistance
gene cassette (10) and a thymidine kinase (PGK-TK) expression
cassette (11). E129/Cj embryonic stem cells (5 
 
3
 
 10
 
6
 
) were elec-
troporated with 20
 
 m
 
g of linearized targeting vector DNA. The
embryonic stem cells were cultured onto G418 resistant murine
fibroblasts and selection, in the presence of 300 
 
m
 
g/ml G418 and
2 
 
m
 
M Gancylovir, was initiated 48 h after electroporation. Dou-
ble-resistant colonies were isolated after 10 d. PCR screening for
homologous recombination was carried out using the diagnostic
primers spanning the PGKneo and the short arm of the construct
(see Fig. 2 A). Homologous recombination was subsequently
confirmed by EcoRI digestion of genomic DNA and hybridiza-
tion with probe A (see Fig. 2). Chimeric mice were produced by
injection of embryonic cells into 3.5-d-old blastocysts (10). The
contribution of embryonic stem cells to the germline of chimeric
mice was assessed by breeding with C57BL/6 mice, and germline
transmission of the PNP mutation was confirmed by Southern
blot analysis of tail DNA. Mice heterozygous for the mutant gene
were interbred to homozygosity.
 
Enzyme Assays.
 
PNP enzymatic activity was assayed in cell
lysates using cellulose TLC with [8-
 
14
 
C]inosine (50 mCi/mmol;
Moravek Biochemicals, Inc.) as substrate, as described previ-
ously (3).
Deoxyguanosine kinase activity was assayed with [8-
 
3
 
H]2
 
9
 
-
deoxyguanosine (4 mCi/mmol, Moravek Biochemicals, Inc.) as
described (12).
 
Analysis of Intracellular Nucleosides, GTP, and dGTP Pools.
 
In-
tracellular nucleotides were extracted with 0.4 M ice-cold per-
chloric acid as described previously (13). After 5 min on ice, the
cell extract was neutralized with 0.5 M tri-
 
n
 
-octylamine dissolved
in 1,1,2-trichlorotrifluoroethane in the presence of 0.1% bro-
mophenol blue until the solution changed to blue. Samples were
centrifuged at 15,000 
 
g
 
 for 1 min and frozen at 
 
2
 
70
 
8
 
C until ana-
lyzed (14). Mitochondria were isolated by differential centrifuga-
tion (15). Nucleotides were separated on a Hewlett-Packard
model 10848 chromatograph using a Partisil-5-SAX column
(Whatman, Inc.; reference 3). Urinary nucleosides and deoxynu-
cleosides were analyzed by reverse phase HPLC as described pre-
viously (3). Intracellular dGTP analysis was performed by the
DNA polymerase method described by Sherman and Fyfe (16).
Urinary nucleosides were determined using a C-18 reverse phase
HPLC column (17).
 
Flow Cytometric Analysis.
 
Flow cytometry was performed us-
ing a dual laser FACScan™ (Becton Dickinson). Single cell sus-
pensions (10
 
6
 
 cells) of either thymi, spleen, lymph node, or bone
marrow were stained for three-color fluorescence analysis. Fluo-
rescein-conjugated antibodies included CD3, TCR, IgM, and
CD45 or CD34. Phycoerythrin-conjugated antibodies included
CD4, CD11b, CD14, CD43, and Sca-1. Biotin-conjugated anti-
bodies included CD8, IgM, NK1.1, CD19, B220, CD25, and
CD24, and were developed with CyChrome-strepavidin. All an-
tibodies were purchased from BD PharMingen. Control antibod-
ies were FITC–Leu-4, PE–Leu-4, and biotin–Leu-1 (Becton
Dickinson).
Anti–Fc receptor (CD16) antibody was used in all populations
except thymus. Cells were washed in phosphate buffer containing
0.1% bovine albumin with 0.01% sodium azide (staining buffer)
at 4
 
8
 
C. Pellets were then stained with the FITC-conjugated anti-
body at 4
 
8
 
C for 15 min, after which PE-conjugated antibody was
added, and cells were further incubated for 30 min at 4
 
8
 
C. After
washing twice in staining buffer, cells were stained with biotin-
conjugated antibodies and incubated for 20 min at 4
 
8
 
C. Cy-
Chrome strepavidin was added after washing, and after a further
incubation of 15 min, cells were washed and resuspended in 0.5
ml of staining buffer, and were analyzed after filtering through a
0.8-
 
m
 
m filter and the addition of propidium iodide.
All fluorescence data were collected using logarithmic amplifi-
cation on 10–50 K viable cells as determined by forward/side
scatter and propidium iodide exclusion.
 
Determinations of Apoptosis.
 
Annexin V binding was per-
formed according to the manufacturer’s instructions (Boeh-
ringer). In some experiments, as indicated, thymocytes were
stained as described above with a combination of PE- and biotin–
CyChrome-conjugated antibodies before annexin V staining.
Previous experiments showed that the antibodies did not inter-
fere with the annexin V stain. The PNP inhibitor, CI-1000 (2-
amino 3,5-dihydro-7-[3-thienylmethyl]-4H-pyrrolo[3,2-d]-pyri-
midin-4-one HCl), used in the apoptosis experiments were a gift
of Dr. R.B. Gilbertsen (Parke-Davis). Mice overexpressing Bcl2
in thymocytes (described by Sentman et al. [18]) were obtained
from The Jackson Laboratory.
Dissipation of mitochondrial membrane potential (
 
Dc
 
m
 
) was
determined using potentiometric sensitive fuorochrome, 3,3
 
9
 
 di-
hexyloxacarbocyanine iodide (DiOC
 
(6)3
 
; 20 nM) (19). Caspase
activity was inhibited by 
 
N
 
-benzoyloxycarbonyl-Val-Ala-Asp
fluoromethylketone (Z-VAD.fmk; 50 
 
m
 
M).
Apoptotic nuclear DNA fragmentation was measured by the
terminal deoxynucleotidyl transferase (TdT)-mediated dUTP
nick end labeling (TUNEL) technique using an FITC-conju-
Figure 1. A schematic presentation of the role of PNP in the degrada-
tion and salvage pathways of purine nucleosides is depicted. PNP catalyzes
the phosphorolysis of the products of the ADA reaction, inosine and
deoxyinosine, to yield hypoxanthine and ribose-1-phosphate. Deficiency
in PNP enzymatic activity leads to the accumulation of its substrates:
inosine, deoxyinosine, guanosine, and deoxyguanosine. Of the four PNP
substrates, only deoxyguanosine is phosphorylated by the mitochondrial
deoxyguanosine kinase (dGK). Further phosphorylation of dGMP leads to
the accumulation of dGTP, which may interfere with DNA synthesis or
repair directly or by inhibition of ribonucleotide reductase activity. The
PNP product guanine is salvaged back to the guanine nucleotide pools by
hypoxanthine guanine phosphorybosyl transferase (HGPRT) activity. 
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gated dUTP kit (Boehringer) according to the manufacturer’s in-
structions. The frequency of apoptotic cells as detected by frag-
mented nuclear DNA was determined by flow cytometry.
 
Cell Isolations and Cultures.
 
Thymocytes were cultured for
the amounts of time indicated, ranging from 2–12 h in complete
medium (RPMI with 10% FCS, 0.1 M glutamine, and 0.05 M
Hepes with 2
 
 3 
 
10
 
2
 
5 
 
M 2-ME at 5 
 
3 
 
10
 
6 
 
cells/ml in 24-well
plates; Costar). In some experiments, TCR was cross-linked us-
ing purified anti-TCR mAb (20 
 
m
 
g/ml) and anti-CD3 mAb
(145-2C11 mAb; 20
 
m
 
g/ml), anti-CD4 mAb 1:4 vol of superna-
tant (RL172 [20]), and anti-CD8 mAb supernatant (3-155
 
 
 
[20])
for the time of culture. Cells were then washed and tested for ap-
optosis using the annexin V staining. Evidence for cross-linking
was performed in these cultured cells by staining for the antigen
being cross-linked with a specific mAb directed to this antigen.
Purified T cells derived from both lymph nodes and spleen of
PNP-deficient as well as control mice were obtained by nylon
wool depleting these populations. In brief, 5 
 
3 
 
10
 
7 
 
cells nylon
wool–packed (Robbins Scientific) were poured into 10- or 20-
ml syringes. Columns were preincubated for 45 min with the sy-
ringe volume of 1% BSA-PBS, and cells were loaded in 1–3 ml
and incubated for another 45 min. Cells were then eluted with
two column volumes, washed, and stained for CD3, CD11, and/
or IgM mAb. Nylon wool lymph node T cells were on average
 
.
 
90% pure (range 86–98% in
 
 n 
 
5 
 
16 experiments).
 
Cytotoxic T Cell Assay.
 
Purified T cells derived from the
spleens of PNP-deficient (H-2
 
b
 
) or wild-type controls were co-
cultured with 20 cGy gamma-irradiated splenocytes derived from
either CBA (H-2
 
k
 
) or DBA/2 (H-2
 
d
 
) at 10 
 
3
 
 10
 
6
 
 responder with
10 
 
3 
 
10
 
6
 
 irradiated stimulators in 20 ml final volume in flasks.
Half of the cultures were supplemented with a previously tested
optimal dose of rIL-2 (provided by Dr. R. Miller, University of
Toronto, Toronto, Ontario). After 5 d, recovered cells were
counted and used in a 4-h chromium assay at E/T ratios ranging
from 3–100:1 in u-shaped 96-well plates. Each culture was as-
sayed against the haplotype of the stimulator used, third party
stimulator or syngeneic H-2
 
b
 
. The tumor cell lines (3,000 cells per
well) P815 (H-2
 
d
 
) and BW5467 (H-2
 
k
 
) were used as targets.
Percentage cytotoxicity was calculated as (experimental release
 
2
 
 spontaneous release)/(total release 
 
2
 
 spontaneous release) 
 
3
 
100. Spontaneous releases were 
 
,
 
12%.
 
Gamma Irradiation and T Lymphocyte Proliferation Assay.
 
For
gamma irradiation experiments, T cells from the thymus or spleen
were suspended in RPMI 1640 with 10% FCS at 10 
 
3 
 
10
 
6
 
 cells/
ml, and were exposed to varying doses of gamma irradiation from
a 
 
137
 
Cs irradiator. Total spleen or lymph node cells (3 
 
3 
 
10
 
5
 
 cells)
or nylon wool–purified T cells (3 
 
3
 
 10
 
5
 
 cells) were cultured in
complete medium in 96 flat-bottomed plates (Costar) in the pres-
ence or absence of Con A (2 
 
m
 
g/ml) and IL-2 (10 U/ml). Lym-
phocyte proliferation was measured after 72 h. 1 
 
m
 
Ci [
 
3
 
H]thymi-
dine was added 4 h before the termination of the cultures.
 
Results
 
Generation of PNP-deficient Mice.
 
We used homologous
recombination to generate a mouse line that lacks PNP ac-
tivity by replacing a 1.2-kb PNP gene fragment containing
the catalytic site (nucleotides 324–870 spanning exons 3
and 4) with a neomycin (PGK
 
neo
 
) gene cassette (reference
11; Fig. 2). The selected PNP-deficient stem cell clones
were injected into blastocysts of C57BL/6 mice to generate
129/C57BL/6 chimeric mice. After germline transmission
 
of the targeted DNA, PNP
 
2
 
/
 
2
 
 homozygosity was diag-
nosed using PCR of tail DNA and PNP enzyme assays
(
 
,
 
0.2% of PNP
 
1
 
/
 
1
 
).
 
Metabolic Abnormalities in PNP-deficient Mice.
 
To under-
stand the metabolic consequences of PNP deficiency, we
first analyzed the levels of PNP substrates excreted in their
urine. The urine of PNP-deficient mice contains large
amounts of the four PNP substrates (inosine, deoxyinosine,
guanosine, and deoxyguanosine), similar to PNP-deficient
patients (reference 17; Table I A). The intracellular concen-
tration of GTP is reduced in PNP
 
2
 
/
 
2
 
 cells, reflecting the
lack of a guanosine kinase and inability to form (and hence
salvage) guanine (Table I; Fig. 1; references 21, 22). In con-
trast, dGTP pools were elevated by about eightfold in
PNP
 
2
 
/
 
2
 
 cells. As was proposed previously (14), phosphory-
lation of deoxyguanosine, the rate-limiting step in its con-
version to dGTP, may be limited by an unexplained sec-
ondary loss of deoxyguanosine kinase activity found in cells
of PNP-deficient mice (Table I B; Fig. 1; reference 23). In
preliminary studies, we observed a substantial increase in
whole blood PNP activity (20% of wild-type level) in each
of three PNP knockout mice treated with polyethylene
glycol (PEG)-modified PNP, which also eliminated the ex-
cretion of PNP substrates and alleviated the secondary loss
of deoxyguanosine kinase activity (data not shown).
Because deoxyguanosine kinase localizes to the mito-
chondria (24–26), we have analyzed the distribution of in-
Figure 2. PNP targeting. Partial map of the PNP locus (A) and the tar-
geting construct (B), whereby the 1.8-Kb PGKneo cassette (bold) replaces a
1.2 genomic fragment and the targeted locus (C). Diagnostic 1, oligode-
oxynucleotide-TATGCAGTTCTGAATCCTCCCTGTAGCAGG; di-
agnostic 2, deoxyoligonucleotide-TCTACTGCTAGGATCTAAGAA-
CAGAGACTAGTG. Diagnostic 1/diagnostic 2 oligodeoxynucleotides
synthesize a PCR fragment of 3.0 Kb with wild-type DNA as substrate
and two bands of 3.0 Kb (wild-type allele) and 3.8 Kb (recombinant al-
lele). Bottom: Southern blot analysis of representative clones. Genomic
DNA was digested with EcoRI and hybridized with probe A. Genomic
129 DNA and the DNA of nonrecombinant clone contain a nonrecom-
binant band of 7.0 Kb. Four clones (149, 284, 244, and 271) contain the
nonrecombinant and recombinant bands of 7.0 Kb and 7.8 Kb, respec-
tively. 
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tracellular dGTP pools (Table I). We found a marked in-
crease in dGTP associated with washed mitochondria from
PNP-deficient thymocytes compared with mitochondria
from PNP-expressing cells. Consistent with this observa-
tion, incubation of PNP-expressing thymocytes with deoxy-
guanosine in the presence of PNP inhibitor led to a large
accumulation of dGTP in the mitochondria (data not
shown). In contrast, incubation of thymocytes with the
ADA inhibitor deoxycoformycin and deoxyadenosine re-
sulted in a substantial increase of intracellular dATP pools,
but no increase in mitochondrial dATP levels (data not
shown). Thus, the localization of the respective deoxynu-
cleoside kinases determines the intracellular location of
dNTP pools because deoxycytidine kinase, the enzyme
partially responsible for deoxyadenosine phosphorylation
and with low affinity towards deoxyguanosine, is a nuclear
enzyme (27).
 
Abnormalities in Lymphocyte Subpopulations in PNP-deficient
Mice.
 
Analysis of thymocyte subpopulations in PNP
 
2
 
/
 
2
 
3-mo-old mice reveals a twofold increase in the frequency
of immature CD4
 
2
 
CD8
 
2
 
 double negative (DN) cells and a
decrease in the total cell numbers of CD4
 
1
 
CD8
 
1
 
 double
positive (DP) and CD4
 
1
 
 and CD8
 
1
 
 single positive (SP)
thymocytes (Fig. 3 A and Fig. 4 A).
Similar to the thymus, both the spleen and lymph nodes
of PNP-deficient mice exhibit decreased numbers of
CD41 and CD81 T cells (Fig. 3 A and Fig. 4 A). The
spleen and lymph nodes of PNP-deficient mice also show
an increase in the frequency of immature CD191IgM2 pre-B
cells with no concomitant change in the frequency of
IgM1 mature B cells (Fig. 3 B and Fig. 4 B). The spleens of
PNP2/2 mice also contained increased numbers of CD111
myeloid cells (Fig. 4 B).
Table I. Urinary Levels of PNP Substrates, Intracellular Levels of Guanine Nucleotides, and Deoxyguanosine Kinase Activity in Thymocytes 
from PNP-deficient Mice
Urinary purine nucleosides
Mice Inosine Guanosine dInosine dGuanosine
nmol/g creatinine nmol/g creatinine nmol/g creatinine nmol/g creatinine
PNP2/2 46.8 (9.7) 34.5 (7.3) 20.7 (2.7) 16.5 (1.5)
PNP1/2 ,0.5 ,0.5 ,0.5 ,0.5
Intracellular guanine nucleotides
Thymocytes dGTP GTP Deoxyguanosine kinase Mitochondrial dGTP
pmol/106 cells pmol/106 cells pmol/mg/min pmol/mg protein
PNP2/2 17.3 (2.8) 695.7 (25.4) 6.3 (0.9) 0.45 (0.08)
PNP1/2 2.2 (0.74) 971.4 (32.8) 130.2 (9.8) ,0.05
Nucleoside, deoxynucleoside, nucleotide, and deoxynucleotide levels and enzymatic activities were determined as described in Materials and
Methods. Top: urinary nucleoside levels normalized to creatinine levels are averages of five individual daily measurements, with SD given in
parentheses. Bottom: thymocyte dGTP, GTP, and deoxyguanosine levels represent averages of four individual mice, with SD given in parentheses.
Figure 3. T and B lymphocyte subpopulations in lymphoid organs of
PNP-deficient mice. Single-cell suspensions of thymocytes, splenocytes,
and lymph node cells from 9-wk-old PNP-deficient mice and their het-
erozygous littermates were stained for three-color fluorescence analysis.
Cells were first reacted with CD3 mAb (2C11-145 FITC conjugated)
and CD4 mAb (RM4.5 PE conjugated), then with CD8 mAb (53-6.7 bi-
otin conjugated), and finally with CyChrome-streptavidin. Top: percent-
age of cells in the individual subpopulation are shown in each quadrant.2201 Arpaia et al.
Lymphocyte Function in PNP-deficient Mice. We assessed
the function of T cells from PNP-deficient mice and tested
the ability of cytotoxic T cells to specifically kill in a mixed
lymphocyte reaction against H-2k– and H-2d–bearing stim-
ulator cells. PNP-deficient spleen cells (H-2b) were cocul-
tured for 5 d in the presence of irradiated spleen cells de-
rived from either DBA/2 mice (H-2d; data not shown) or
CBA mice (H-2k; Fig. 5). The cultures were set up in the
presence or absence of IL-2. Recovered cells were then
tested in a 4-h 51Cr-release assay for their ability to lyse al-
logeneic H-2k targets or third party H-2b targets. In the ab-
sence of exogenous IL-2, H-2k–stimulated PNP-deficient
T cells were unable to kill either H-2k–bearing or H-2d–
bearing targets. However, in the presence of IL-2, the abil-
ity of PNP-deficient T cells to kill allogeneic H-2k cells
was restored to a level comparable to that of their heterozy-
gous littermates (Fig. 5). This observation suggests that T
cells from PNP-deficient mice have an impaired ability to
mount an immune response in the absence of exogenously
added IL-2.
Enhanced Thymocyte Apoptosis in PNP Deficiency Is Initiated
in the Mitochondria. To examine whether the depletion of
DP thymocytes is due to enhanced apoptosis, we analyzed
the frequency of apoptotic cells in thymocyte subpopula-
tions from PNP2/2 mice and their heterozygous littermates
(Fig. 6). Freshly isolated PNP-deficient thymocytes show a
twofold increase in the frequency of apoptotic thymocytes,
measured by annexin V binding (28), compared with their
heterozygous littermates. The frequency of apoptotic cells
in the PNP2/2 thymocyte subpopulation is inversely re-
lated to Bcl2 expression: it is highest at the DP stage (8.7%
of total PNP2/2 DP cells), lower in SP CD4 and CD8
cells, and absent in immature DN cells.
To examine whether Bcl2 expression in the thymus may
offer protection from apoptosis caused by PNP deficiency,
we incubated thymocytes from C57BL/6 and Bcl2 trans-
genic mice (overexpressing Bcl2 in the thymus [18]) in the
presence of deoxyguanosine and a PNP inhibitor (29). The
frequency of apoptotic cells was monitored by annexin V
binding. PNP inhibition in the presence of deoxygua-
Figure 4. Total numbers of
lymphocyte subpopulations in
the thymus, spleen, and lymph
nodes of PNP-deficient mice.
(A) Total numbers of cells per
thymus of thymocyte subpopula-
tions recovered from thymi of
PNP2/2 (white bars) and PNP1/2
(black bars) 9–12-wk-old mice
were analyzed by three-color
flow cytometry for DN (CD42
CD82), DP (CD41CD81), and
SP CD41CD82 or CD42CD81
thymocytes. Results are means of
eight independent experiments
with one to three mice each.
Vertical bars represent the SD.
(B) Total numbers of T cells
(CD31), B cells (IgM1), pre-B
cells (CD191IgM2), and my-
eloid cells (CD111) are averages
of eight experiments.
Figure 5. Analysis of alloge-
neic cytotoxic T cell response of
PNP2/2 lymphocytes. Spleno-
cytes derived from PNP2/2 (tri-
angles) or PNP1/2 (squares)
mice were cultured for 5 d with
allogeneic irradiated (20 cGy)
CBA (H-2k) splenocytes in the
presence (B) or absence (A) of
IL-2. On day 5, cytotoxic T cell
function was assayed at the indi-
cated E/T ratios in a 4-h chro-
mium-release assay against
BW5437 (H-2k) targets (filled
symbols) or third-party P815
(H-2d) targets (open symbols).2202 Purine Nucleoside Phosphorylase–deficient Immune-deficient Mice
nosine caused increased thymocyte apoptosis in C57BL/6
(Fig. 7). Deoxyguanosine or PNP inhibitor added sepa-
rately did not affect the frequency of apoptotic thymocytes.
Overexpression of Bcl2 in thymocytes from transgenic
mice completely protects against deoxyguanosine-induced
apoptosis in the absence of PNP activity. No apoptosis was
induced by any of the other three PNP substrates (inosine,
deoxyinosine, or guanosine) in the presence of the PNP in-
hibitor (data not shown).
Dissipation of Dcm is an early apoptotic event that is in-
dependent of caspase activity for intramitochondrial apop-
totic agents, but Dcm is dependent on caspase activity if the
apoptotic signal is extramitochondrial (19). Thus, resistance
of Dcm to caspase inhibition is indicative of apoptotic sig-
nals that originate within the mitochondria. Deoxygua-
nosine in the presence of PNP inhibitor caused rapid dissi-
pation of Dcm, similar to other apoptosis-inducing agents.
This dissipation of Dcm was resistant to cytosolic caspase
inhibition, indicating that deoxyguanosine initiates apopto-
sis within the mitochondria (Fig. 8). In contrast, the deoxy-
guanosine-induced fragmentation of nuclear DNA, a late
event in apoptosis, was inhibited by caspase inhibitor.
These results are consistent with the hypothesis that accu-
mulation of dGTP in the mitochondria is responsible for
the apoptosis observed in PNP-deficient thymocytes.
Sensitivity of PNP-deficient T Cells to Gamma Irradiation.
Imbalance of dNTP pools has been shown to interfere
with DNA repair (5, 30–32). We have examined the possi-
bility that mitochondrial dGTP accumulation may predis-
pose PNP-deficient T cells to DNA damage. Thymocytes
from PNP-deficient mice exhibit increased sensitivity to
gamma irradiation compared with their heterozygous lit-
termates. After 12 h of incubation after gamma irradiation,
in PNP2/2 thymocytes, 50% apoptosis was observed at
about 200 cGy, whereas a dose of 1,000 cGy was needed to
induce 50% apoptosis in thymocytes from heterozygous
mice (Fig. 9).
To assess the sensitivity of peripheral T cells to gamma
irradiation, splenocytes from PNP-deficient mice and their
heterozygous littermates were gamma irradiated, and their
proliferation was monitored after stimulation by Con A
(Fig. 10). Exogenous IL-2 was added to all cultures, as
PNP-deficient T cells have decreased mitogenic response
Figure 6. Increased frequency of apoptotic cells in freshly isolated thy-
mocytes in PNP-deficient mice. Three-color analysis of apoptotic thy-
mocyte subpopulations was carried out in freshly isolated thymocytes
stained with conjugated fluorescent antibodies against CD4 and CD8, and
then stained with conjugated annexin V as described in Materials and
Methods. The frequencies of annexin V–positive apoptotic cells in DP,
CD41 (CD4sp), CD81 (CD8sp), and DN thymocyte subpopulations of
PNP2/2 and heterozygous littermates are presented. Data from a single ex-
periment representative of five additional experiments with similar results.
Figure 7. Effect of Bcl2 overexpression on thymocyte apoptosis in-
duced by deoxyguanosine in the presence of a PNP inhibitor. Thy-
mocytes from C57BL/6 and BCl2TG mice were incubated in RPMI
1640 medium with 10% FCS in the presence or absence of 60 mM de-
oxyguanosine and 20 mM of the PNP inhibitor CI-1000 (2-amino 3,5-
dihydro-7-(3-thienylmethyl)-4H-pyrrolo[3,2-d]-pyrimidin-4-one HCl)
as indicated for 12 h, and the frequency of CD41CD81 DP apoptotic
cells was analyzed by annexin V staining.2203 Arpaia et al.
in the absence of IL-2 (data not shown; references 9, 33).
Similar to PNP-deficient thymocytes, mature T cells from
the spleens of PNP-deficient mice are more sensitive to
gamma irradiation (90% reduction at 300 cGy) than their
heterozygous littermates (90% reduction at 800 cGy).
These observations are consistent with an impaired DNA
repair in PNP-deficient thymocytes.
Discussion
In humans, PNP gene mutations that result in extensive
loss of enzymatic activity cause severe T cell deficiency
with variable abnormalities in humoral immunity (2, 34–
37). Similar to the human disease, PNP deficiency in mice
causes an immunodeficiency that affects T lymphocytes
more severely than B lymphocytes. PNP knockout mice
exhibit impaired thymocyte differentiation (Fig. 3), re-
duced mitogenic and allogeneic responses (Fig. 5; data not
shown), and decreased numbers of maturing thymocytes
and peripheral T cells (Fig. 3 and Fig. 4 A). Mice with less
complete PNP deficiency because of missense mutations
showed a more gradual postnatal decline in T cell numbers
and in T cell function (9, 33). PNP knockout mice pro-
vide a good experimental model for studying the biochem-
ical basis of immunodeficiency, and for testing potential
therapies for the disease in humans. Preliminary studies
suggest that a previously developed PEG-PNP that shows
reduced immunogenicity in normal mice (38) corrects the
metabolic abnormalities and prolongs the life of PNP
knockout mice.
The immune deficiency disease caused by loss of PNP
enzymatic activity could be due to either interference with
purine salvage resulting in depletion of GTP or to the ac-
Figure 8. Effects of inhibition of caspase activity on deoxyguanosine-
induced Dcm dissipation and nuclear DNA fragmentation. Thymocytes
from C57BL/6 mice were incubated in RPMI 1640 medium with 10%
FCS in the presence or absence of 60 mM deoxyguanosine and 20 mM of
the PNP inhibitor CI-1000 (2-amino 3,5-dihydro-7-(3-thienylmethyl)-
4H-pyrrolo[3,2-d]-pyrimidin-4-one HCl) as indicated for 12 h. Dcm was
determined using potentiometric sensitive fuorochrome, DiOC(6)3 (20
nM; reference 19). Percentages of cells with dissipated Dcm are indicated
above the bar covering area of cells with lower DiOC6 fluorescence in-
tensity. Caspase activity was inhibited where indicated by Z-VAD.fmk
(50 mM). Nuclear DNA fragmentation was measured by the TUNEL
technique as described in Materials and Methods. Percentages of apop-
totic cells are indicated above the bars.
Figure 9. Effect of gamma irradiation on thymocyte apoptosis in PNP-
deficient mice. Thymocytes from PNP-deficient mice (j) and their het-
erozygous littermates (h) were suspended in RPMI 1640 medium with
10% FCS, and were gamma irradiated with the indicated dose. Irradiated
thymocytes (106 ml) were incubated in RPMI 1640 medium with 10%
FCS for 12 h, and the frequency of apoptotic cells was monitored by an-
nexin V binding as described in Materials and Methods. Averages of an-
nexin V–negative cells of three different experiments using two to three
mice each.
Figure 10. Effect of gamma irradiation on T cell proliferation in PNP-
deficient mice. Purified T cells from PNP-deficient mice (j) and their
heterozygous littermates (h) were gamma irradiated at the indicated dos-
age, and equal numbers of T cells (3 3 105) were aliquated in quadrupli-
cates onto microtiter plates containing 0.2 ml RPMI 1640 medium with
10% FCS in the presence of 2 mg/ml Con A and IL-2 (10 U/ml). T cell
proliferation was measured after 4 h of [3H]thymidine pulse. Results are
averages of quadruplicate wells. Three independent experiments using
two to three mice each gave similar results.2204 Purine Nucleoside Phosphorylase–deficient Immune-deficient Mice
cumulation of one or more of the PNP substrates inosine,
guanosine, deoxyinosine, and deoxyguanosine. Decreased
intracellular levels of GTP observed in PNP deficiency
(Table I) are unlikely to contribute to the immune dys-
function, as a similar decrease in intracellular levels of GTP
in hypoxanthine guanine phosphorybosyl transferase (HG-
PRT) deficiency has no effect on immune function in pa-
tients with Lesch-Nyan syndrome (39). The only other in-
tracellular metabolic abnormality in PNP2/2 mice, as well
as in PNP1/2 mice, is the expansion of intracellular dGTP
pools (Table I), which are normally tightly regulated in
mammalian cells (40, 41).
The observed increase in intracellular dGTP pools in
PNP deficiency is modest (17 pmol/106 cells, or eightfold
normal levels) compared with the 4–5 mM concentration
of deoxyguanosine accumulated in the urine of these mice
(Table I). This may be partly explained by end product in-
hibition of deoxyguanosine kinase activity by dGTP (42,
43). In addition, cells from PNP2/2 mice exhibit a second-
ary loss of deoxyguanosine kinase activity in all tissues ex-
amined, further limiting the potential of deoxyguanosine
accumulation (Table I B; reference 14). The underlying
mechanisms have not been established, although partial res-
toration of deoxyguanosine kinase activity after treatment
with PEG-PNP clearly indicates an effect of a PNP sub-
strate or metabolite. It is not clear whether deoxyguanosine
kinase activity is reduced in cells of human patients with
PNP deficiency. However, in PNP-deficient mice, this ef-
fect is likely to moderate the immune dysfunction, and per-
haps prevents the neurologic abnormalities often present in
human patients.
The observations described here, particularly the evi-
dence that dGTP accumulation occurs selectively in mito-
chondria (Table I) and that PNP-deficient thymocytes and
splenic T cells show increased sensitivity to irradiation (Ta-
ble I; Fig. 10), offer new insight into the biochemical basis
for immunodeficiency. We postulate that accumulation of
dGTP in the mitochondria of T lymphocytes initiates apop-
tosis by interfering with the repair of mitochondrial DNA
damage. This hypothesis is supported by several observa-
tions. The mitochondrial and T cell specificity of dGTP
accumulation are consistent with the subcellular localiza-
tion (44) and tissue distribution (13, 45, 46) of deoxygua-
nosine kinase activity. Human deoxyguanosine kinase ac-
tivity is localized exclusively in the mitochondria, and thus
dGTP accumulates as expected in the mitochondria (47).
That dGTP accumulation preferentially inhibits mitochon-
drial DNA synthesis or repair rather than nuclear DNA
synthesis is suggested by the finding that PNP-deficient
cells are sensitive to gamma irradiation, but are able to rep-
licate their nuclear DNA in response to mitogen in the
presence of IL-2 (Fig. 10).
Other observations provide additional evidence that the
T cell damage in PNP deficiency originates in the mito-
chondria. Overexpression of deoxyguanosine kinase in the
mitochondria leads to increased sensitivity to anticancer
deoxyguanosine analogues (48). dGTP-mediated inhibition
of mitochondrial DNA synthesis or repair might also initiate
apoptosis by inducing release of cytochrome C into the cy-
toplasm.
Recently, the mutations responsible for the human mito-
chondrial disease neurogastrointestinal encephalomyopathy
(MNGIE) were localized to the thymidine phosphorylase
(TP) gene. TP phosphorylates thymine to yield thymidine,
and thus has parallel activity in the pyrimidine salvage path-
way to that of PNP in the purine salvage pathway (49). Pa-
tients with MNGIE syndrome have multiple deletions in
their mitochondrial DNA and develop a muscular neuro-
logical disorder starting in their twenties. It has been postu-
lated that dTTP accumulation in the mitochondria of these
patients may be responsible for abnormalities in mitochon-
drial DNA synthesis and repair (49). Although the tissue-
specific phenotype in the two diseases may vary according
to the specific tissue expression of the respective kinases, it
is likely that the neurological defects, including cerebral
ataxia, common to PNP-deficient and MNGIE patients
(35, 50–52) may similarly be due to inhibition of mito-
chondrial DNA maintenance by either dGTP or dTTP
(Fig. 11).
Figure 11. Proposed mechanism of PNP, ADA, and TP deficiencies.
Mutations in the cytosolic enzymes PNP and TP result in accumulation
of deoxyguanosine (GdR) and thymidine (TdR), respectively. The accu-
mulated deoxynucleosides are phosphorylated by the mitochondrial en-
zymes deoxyguanosine kinase (GdR kinase; reference 47) or thymidine
kinase (TdR kinase; reference 61), resulting in the accumulation of dGTP
and dTTP, respectively. The abnormal accumulation of dNTP may inter-
fere with mitochondrial DNA synthesis, or repair directly or by inhibition
of mitochondrial ribonucleotide reductase (mRR; reference 62), leading
to apoptosis. In contrast, ADA deficiency leads to the accumulation of
dATP in the nucleus because of nuclear localization of deoxycytidine ki-
nase, the enzyme responsible for deoxyguanosine phosphorylation (refer-
ence 27). Accumulation of dATP leads to apoptosis in a p53-dependent
manner by inhibiting nuclear ribonucleotide reductase (nRR), interfering
with DNA repair, and by directly participating in caspase activation (ref-
erences 7, 31, 60).2205 Arpaia et al.
The T lymphocyte specificity of PNP deficiency may be
due in part to the increased capability of T cells and thy-
mocytes to accumulate purine dNTPs (13, 53, 54). On the
other hand, stimulation of T cell thymocytes through their
antigen receptor often leads to activation-induced apopto-
sis, a process that requires activation threshold to recruit the
mitochondrial apoptotic apparatus (55, 56). It is thus possi-
ble that mitochondrial dGTP accumulation in PNP defi-
ciency will lower that apoptotic threshold.
Mitochondrial DNA repair is of critical importance in
view of the increased frequency of mitochondrial DNA
damage compared with nuclear DNA (20-fold higher;
reference 57). The immediate effects of deoxyguanosine-
induced apoptosis suggest the existence of an early detection
mechanism of accumulation of mitochondrial DNA dam-
age leading to the activation of mitochondrial apoptosis.
The mechanisms that link nuclear DNA damage to apop-
tosis are under intensive investigation and include the par-
ticipation of p53, ataxia telangiectesia mutated gene
(ATm), and possibly dATP (7, 58–60). In contrast, little is
known about the mechanisms that link mitochondrial DNA
damage to apoptosis. Changes in mitochondrial dNTP lev-
els such as dGTP and dTTP may participate in linking mi-
tochondrial DNA damage to apoptosis, analogous to the
role of dATP in apoptosis and in nuclear DNA repair (7,
60). The PNP-deficient mice provide an excellent model
to test this hypothesis further.
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